CTOs on the Move

San Miguel Technology

www.fsanmiguel.com

 
San Miguel Technology Llc is a Landenberg, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Princeton BioMolecular Research Inc

Princeton BioMolecular Research Inc is a Monmouth Junction, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Arcturus Therapeutics

Arcturus Therapeutics is a preclinical drug delivery and nucleic acid medicines company. We are focused on developing novel technologies to build the next generation of safe, effective RNA and DNA medicines. We have proprietary technologies, validating partnerships, and an experienced team with deep expertise in delivery and nucleic acid-based therapeutics. Arcturus Therapeutics is presently recruiting outstanding candidates with experience in the field of RNA technologies and nanoparticle sciences. Only exceptional applicants need apply. Compensation and equity position is commensurate.

Deltagen

Deltagen is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Adcentrx Therapeutics

Adcentrx Therapeutics is a biotechnology company focused on accelerating breakthroughs in protein conjugate therapeutic development for cancer and other life-threatening diseases.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.